Alyeska Investment Group
BCAB icon

Alyeska Investment Group’s BioAtla BCAB Stock Holding History

Alyeska Investment Group’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-800
Closed -$1.36M – 733
2020
Q4 		$1.36M Buy
+800
New +$1.34M 0.02% 398

Other funds holding BCAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Alyeska Investment Group's BCAB Position: Q1 2021 in Review

Alyeska Investment Group sold out of BioAtla (BCAB) in Q1 2021, closing a stake of 800 shares — an estimated $1.36M sold.

Alyeska Investment Group first reported a position in BCAB in Q4 2020 and held it in 1 quarter. The position peaked at $1.36M in Q4 2020. 62 funds tracked by Wall St. Rank hold BCAB as of Q1 2021.

  • Alyeska Investment Group reported no remaining BioAtla position as of Q1 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 800 BioAtla shares in Q1 2021, an estimated $1.36M.
  • Alyeska Investment Group first reported a position in BioAtla in Q4 2020 and held it in 1 quarter.
  • Alyeska Investment Group's BioAtla position peaked at $1.36M in Q4 2020.
  • 62 funds tracked by Wall St. Rank held BioAtla as of Q1 2021.

Based on Alyeska Investment Group's 13F filing for Q1 2021, filed 17 May 2021.